[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Antipyrine is combined with Zuclopenthixol.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Zuclopenthixol.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Zuclopenthixol.]
[M04AB02, sulfinpyrazone, The metabolism of Zuclopenthixol can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Zuclopenthixol.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Zuclopenthixol.]
[N05AL01, sulpiride, Zuclopenthixol may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Zuclopenthixol.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Zuclopenthixol.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Zuclopenthixol.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Zuclopenthixol.]
[G03BA03, testosterone, The metabolism of Zuclopenthixol can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Zuclopenthixol can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, Zuclopenthixol may increase the hypotensive activities of Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[N04BC07, apomorphine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Zuclopenthixol.]
[L04AX02, thalidomide, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Zuclopenthixol.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Zuclopenthixol.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Zuclopenthixol.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Zuclopenthixol.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Zuclopenthixol.]
[N05AB08, thioproperazine, Thioproperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05AC02, thioridazine, Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Zuclopenthixol.]
[C01BB04, aprindine, The metabolism of Zuclopenthixol can be decreased when combined with Aprindine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Zuclopenthixol can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tilidine.]
[S01ED01, timolol, Timolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[M02AX02, tolazoline, Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Zuclopenthixol.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Zuclopenthixol is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Zuclopenthixol can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Zuclopenthixol.]
[S01BA05, triamcinolone, The metabolism of Zuclopenthixol can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Zuclopenthixol.]
[C03AA06, trichlormethiazide, Zuclopenthixol may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trifluperidol.]
[N05AA05, triflupromazine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Zuclopenthixol.]
[R03BA07, mometasone, The metabolism of Zuclopenthixol can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Zuclopenthixol.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Trimethadione.]
[C02BA01, trimethaphan, Zuclopenthixol may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[R06AC04, tripelennamine, The metabolism of Zuclopenthixol can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Zuclopenthixol.]
[A03BB01, butylscopolamine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Zuclopenthixol can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Zuclopenthixol can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Zuclopenthixol.]
[C09CA09, azilsartan medoxomil, Zuclopenthixol may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Zuclopenthixol.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Zuclopenthixol.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Zuclopenthixol can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Zuclopenthixol can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Zuclopenthixol can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Zuclopenthixol can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Zuclopenthixol.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Zuclopenthixol.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Zuclopenthixol.]
[B01AC24, ticagrelor, The metabolism of Zuclopenthixol can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N06AX09, viloxazine, The metabolism of Zuclopenthixol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Zuclopenthixol.]
[C04AX07, vincamine, Zuclopenthixol may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Zuclopenthixol.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Zuclopenthixol.]
[A11HA03, vitamin E, The metabolism of Zuclopenthixol can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Zuclopenthixol.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Xenon.]
[C03BA10, xipamide, Zuclopenthixol may decrease the antihypertensive activities of Xipamide.]
[S01AA13, fusidic acid, The metabolism of Zuclopenthixol can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Zuclopenthixol can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Zuclopenthixol.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Zuclopenthixol.]
[R03DC01, zafirlukast, The metabolism of Zuclopenthixol can be decreased when combined with Zafirlukast.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zuclopenthixol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Zuclopenthixol.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Zuclopenthixol can be decreased when combined with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Zuclopenthixol.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Zuclopenthixol.]
[G04BD07, tolterodine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[J02AC03, voriconazole, The metabolism of Zuclopenthixol can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Zuclopenthixol.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Zuclopenthixol.]
[R07AX02, ivacaftor, The metabolism of Zuclopenthixol can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Zuclopenthixol can be increased when combined with Prednylidene.]
[G04BE10, avanafil, Zuclopenthixol may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[A08AA11, lorcaserin, The metabolism of Zuclopenthixol can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Zuclopenthixol can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Zuclopenthixol can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Zuclopenthixol can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Zuclopenthixol.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Zuclopenthixol.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Zuclopenthixol.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Zuclopenthixol.]
[J05AE04, nelfinavir, The metabolism of Zuclopenthixol can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[N04BD02, rasagiline, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Zuclopenthixol.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Zuclopenthixol.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zuclopenthixol.]
[R06AC06, thonzylamine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Zuclopenthixol can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Zuclopenthixol.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Zuclopenthixol.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Zuclopenthixol.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Zuclopenthixol.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Zuclopenthixol.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Zuclopenthixol.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Zuclopenthixol can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Zuclopenthixol may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Zuclopenthixol.]
[G03XC05, ospemifene, The metabolism of Zuclopenthixol can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benperidol.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Zuclopenthixol.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Zuclopenthixol.]
[A06AX06, tegaserod, The metabolism of Zuclopenthixol can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Zuclopenthixol.]
[M01AH01, celecoxib, The metabolism of Zuclopenthixol can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Zuclopenthixol.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Zuclopenthixol.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Zuclopenthixol can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Bepridil is combined with Zuclopenthixol.]
[C02KX05, riociguat, Zuclopenthixol may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Zuclopenthixol may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Zuclopenthixol.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Zuclopenthixol.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Zuclopenthixol can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Zuclopenthixol.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Zuclopenthixol.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Zuclopenthixol.]
[C07AB04, acebutolol, Acebutolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Zuclopenthixol can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Zuclopenthixol can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Zuclopenthixol can be increased when combined with Formestane.]
[N07CA01, betahistine, The therapeutic efficacy of Betahistine can be decreased when used in combination with Zuclopenthixol.]
[S03BA03, betamethasone, The metabolism of Zuclopenthixol can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Betaxolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Zuclopenthixol.]
[L04AC11, siltuximab, The metabolism of Zuclopenthixol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Zuclopenthixol.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Zuclopenthixol.]
[A03BA03, hyoscyamine, Zuclopenthixol may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Zuclopenthixol.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Zuclopenthixol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alfaxalone.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Zuclopenthixol.]
[D11AA01, glycopyrronium, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Zuclopenthixol can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Zuclopenthixol can be increased when combined with Oritavancin.]
[N05AA04, acepromazine, Acepromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Zuclopenthixol.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Zuclopenthixol.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Zuclopenthixol.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Zuclopenthixol.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Zuclopenthixol.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dicoumarol.]
[N06AX11, mirtazapine, Zuclopenthixol may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Zuclopenthixol can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Zuclopenthixol.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Zuclopenthixol.]
[L01XH03, panobinostat, The metabolism of Zuclopenthixol can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Zuclopenthixol can be increased when combined with Acetaminophen.]
[A03AA09, difemerine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Zuclopenthixol can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Zuclopenthixol is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Zuclopenthixol.]
[A04AD14, rolapitant, The metabolism of Zuclopenthixol can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Zuclopenthixol.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Zuclopenthixol.]
[A02BC03, lansoprazole, The metabolism of Zuclopenthixol can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Zuclopenthixol.]
[J02AC05, isavuconazole, The metabolism of Zuclopenthixol can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Zuclopenthixol.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be decreased when combined with Zuclopenthixol.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Zuclopenthixol.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Zuclopenthixol.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Zuclopenthixol.]
[B01AC27, selexipag, Zuclopenthixol may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, Zuclopenthixol may increase the hypotensive activities of Alfuzosin.]
[M04AB05, lesinurad, The metabolism of Zuclopenthixol can be increased when combined with Lesinurad.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Zuclopenthixol.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Zuclopenthixol.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Zuclopenthixol.]
[N04BC01, bromocriptine, Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Zuclopenthixol.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Zuclopenthixol.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amineptine.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Amlodipine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Zuclopenthixol.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Zuclopenthixol.]
[C07AA19, bupranolol, Bupranolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N07BC01, buprenorphine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Zuclopenthixol.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Zuclopenthixol.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Zuclopenthixol.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Artemether.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Zuclopenthixol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Zuclopenthixol.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Zuclopenthixol.]
[S01GX07, azelastine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Zuclopenthixol can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Zuclopenthixol.]
[L01EF02, ribociclib, The metabolism of Zuclopenthixol can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Zuclopenthixol.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Zuclopenthixol.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Beclamide.]
[C09AA07, benazepril, Zuclopenthixol may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zuclopenthixol.]
[D05AX03, calcitriol, The metabolism of Zuclopenthixol can be increased when combined with Calcitriol.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Zuclopenthixol.]
[J05AE09, tipranavir, The metabolism of Zuclopenthixol can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Zuclopenthixol.]
[L04AB02, infliximab, The metabolism of Zuclopenthixol can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Zuclopenthixol can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Zuclopenthixol.]
[N04BD03, safinamide, The therapeutic efficacy of Safinamide can be decreased when used in combination with Zuclopenthixol.]
[L04AC14, sarilumab, The metabolism of Zuclopenthixol can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Zuclopenthixol.]
[D01AC10, bifonazole, The metabolism of Zuclopenthixol can be decreased when combined with Bifonazole.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Zuclopenthixol.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Zuclopenthixol.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Zuclopenthixol.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Zuclopenthixol.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Zuclopenthixol.]
[A02BX12, bismuth subnitrate, Zuclopenthixol may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, Bisoprolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Zuclopenthixol.]
[J05AG03, efavirenz, The metabolism of Zuclopenthixol can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Zuclopenthixol.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brotizolam.]
[R03BA02, budesonide, The metabolism of Zuclopenthixol can be increased when combined with Budesonide.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Zuclopenthixol.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Zuclopenthixol.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Zuclopenthixol.]
[J05AX18, letermovir, The metabolism of Zuclopenthixol can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Zuclopenthixol.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Zuclopenthixol.]
[N01BX04, capsaicin, The metabolism of Zuclopenthixol can be decreased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Zuclopenthixol.]
[C09AA01, captopril, Zuclopenthixol may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Zuclopenthixol can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Zuclopenthixol can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Zuclopenthixol.]
[C07AG02, carvedilol, Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Zuclopenthixol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Zuclopenthixol.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Zuclopenthixol.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be decreased when used in combination with Zuclopenthixol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Zuclopenthixol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Zuclopenthixol.]
[N03AX17, stiripentol, The metabolism of Zuclopenthixol can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Zuclopenthixol can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Zuclopenthixol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Zuclopenthixol.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Zuclopenthixol.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zuclopenthixol.]
[R06AA06, chlorphenoxamine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Zuclopenthixol.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Zuclopenthixol.]
[R03BB08, revefenacin, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Zuclopenthixol can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Zuclopenthixol can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Zuclopenthixol.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Zuclopenthixol.]
[C09AA08, cilazapril, Zuclopenthixol may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Zuclopenthixol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cinitapride.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Zuclopenthixol.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Zuclopenthixol.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Zuclopenthixol.]
[J01FA09, clarithromycin, The metabolism of Zuclopenthixol can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Zuclopenthixol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Zuclopenthixol.]
[N05BA09, clobazam, The metabolism of Zuclopenthixol can be decreased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Zuclopenthixol can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Zuclopenthixol.]
[C09CA06, candesartan, Zuclopenthixol may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Zuclopenthixol can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Zuclopenthixol can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Zuclopenthixol.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Zuclopenthixol.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Zuclopenthixol.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Zuclopenthixol.]
[L01EJ02, fedratinib, The metabolism of Zuclopenthixol can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Entrectinib.]
[N07XX11, pitolisant, The therapeutic efficacy of Pitolisant can be decreased when used in combination with Zuclopenthixol.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Zuclopenthixol.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Zuclopenthixol.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Zuclopenthixol.]
[C03AA09, cyclothiazide, Zuclopenthixol may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Zuclopenthixol.]
[J01DB01, cephalexin, The metabolism of Zuclopenthixol can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Zuclopenthixol can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Zuclopenthixol can be increased when combined with Deflazacort.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Zuclopenthixol.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Zuclopenthixol.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Zuclopenthixol.]
[N03AX25, cenobamate, The serum concentration of Zuclopenthixol can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Zuclopenthixol can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Zuclopenthixol.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Zuclopenthixol.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Zuclopenthixol.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Zuclopenthixol.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Zuclopenthixol.]
[M01AX21, diacetylrhein, The metabolism of Zuclopenthixol can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The metabolism of Zuclopenthixol can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Zuclopenthixol.]
[H02CA02, osilodrostat, The metabolism of Zuclopenthixol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Zuclopenthixol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Zuclopenthixol.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Zuclopenthixol.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Zuclopenthixol.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Zuclopenthixol.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zuclopenthixol.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Zuclopenthixol.]
[M01AH02, rofecoxib, The metabolism of Zuclopenthixol can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Zuclopenthixol can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Clevidipine.]
[C01BD07, dronedarone, Zuclopenthixol may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Valpromide.]
[J01FA13, dirithromycin, The metabolism of Zuclopenthixol can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Zuclopenthixol can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Zuclopenthixol.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zuclopenthixol.]
[C02AA06, methoserpidine, Zuclopenthixol may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Zuclopenthixol.]
[A03AA08, dihexyverine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Zuclopenthixol.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Zuclopenthixol.]
[D07XB03, fluprednidene, The metabolism of Zuclopenthixol can be increased when combined with Fluprednidene.]
[G04BD09, trospium, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Zuclopenthixol.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Zuclopenthixol.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Zuclopenthixol.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Zuclopenthixol.]
[P01BB01, proguanil, The metabolism of Zuclopenthixol can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Remimazolam.]
[N07XX04, sodium oxybate, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Zuclopenthixol can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Zuclopenthixol is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Zuclopenthixol can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Zuclopenthixol can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Zuclopenthixol may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Zuclopenthixol.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05AF03, chlorprothixene, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Zuclopenthixol may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zuclopenthixol.]
[A11CC05, cholecalciferol, The metabolism of Zuclopenthixol can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zuclopenthixol.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Zuclopenthixol.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Zuclopenthixol can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Zuclopenthixol can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Zuclopenthixol.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Zuclopenthixol can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Zuclopenthixol.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Zuclopenthixol.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Finasteride is combined with Zuclopenthixol.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Zuclopenthixol.]
[R03BA03, flunisolide, The metabolism of Zuclopenthixol can be increased when combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The metabolism of Zuclopenthixol can be increased when combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Zuclopenthixol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Zuclopenthixol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Zuclopenthixol can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Zuclopenthixol may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Zuclopenthixol can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Zuclopenthixol.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Zuclopenthixol.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Zuclopenthixol.]
[L01XX73, sotorasib, The serum concentration of Zuclopenthixol can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Zuclopenthixol.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Zuclopenthixol.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Zuclopenthixol.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Zuclopenthixol can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Zuclopenthixol.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Zuclopenthixol.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Zuclopenthixol.]
[J01FF01, clindamycin, Clindamycin may increase the neurotoxic activities of Zuclopenthixol.]
[N06AX25, St. John's wort extract, The metabolism of Zuclopenthixol can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Zuclopenthixol can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Zuclopenthixol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Zuclopenthixol.]
[C10AB01, clofibrate, The metabolism of Zuclopenthixol can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Zuclopenthixol can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Zuclopenthixol.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Zuclopenthixol.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Zuclopenthixol.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Zuclopenthixol.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Zuclopenthixol.]
[C01EB24, mavacamten, The serum concentration of Zuclopenthixol can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Zuclopenthixol.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Zuclopenthixol.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Zuclopenthixol.]
[N05AH02, clozapine, Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Zuclopenthixol.]
[H01AC08, somatrogon, The metabolism of Zuclopenthixol can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Cocaine is combined with Zuclopenthixol.]
[C02KB01, metyrosine, Zuclopenthixol may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Zuclopenthixol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Zuclopenthixol.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Zuclopenthixol.]
[A03AB10, hexocyclium, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Zuclopenthixol.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tropisetron.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Zuclopenthixol.]
[A10BX03, nateglinide, The metabolism of Zuclopenthixol can be decreased when combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Zuclopenthixol can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Zuclopenthixol can be decreased when combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Zuclopenthixol.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Zuclopenthixol.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Zuclopenthixol.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Zuclopenthixol can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Zuclopenthixol.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Zuclopenthixol.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Zuclopenthixol can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lacidipine.]
[N03AX09, lamotrigine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Zuclopenthixol.]
[S01BA03, cortisone, The metabolism of Zuclopenthixol can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Zuclopenthixol.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Loxoprofen.]
[C09AA03, lisinopril, Zuclopenthixol may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Zuclopenthixol can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[H02AB15, meprednisone, The metabolism of Zuclopenthixol can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, Zuclopenthixol may increase the arrhythmogenic activities of Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Zuclopenthixol.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Zuclopenthixol.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Zuclopenthixol.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Cyclobarbital.]
[C03DA04, eplerenone, Zuclopenthixol may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Zuclopenthixol.]
[C03AA07, cyclopenthiazide, Zuclopenthixol may decrease the antihypertensive activities of Cyclopenthiazide.]
[J01FA03, midecamycin, The metabolism of Zuclopenthixol can be decreased when combined with Midecamycin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Zuclopenthixol.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Zuclopenthixol.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Zuclopenthixol.]
[S01XA18, cyclosporine, The metabolism of Zuclopenthixol can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.]
[N06BA07, modafinil, The metabolism of Zuclopenthixol can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Zuclopenthixol.]
[C10AA07, rosuvastatin, The metabolism of Zuclopenthixol can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Zuclopenthixol can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Zuclopenthixol.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Zuclopenthixol.]
[M01AH05, etoricoxib, The metabolism of Zuclopenthixol can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Zuclopenthixol can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Zuclopenthixol.]
[L01DB02, daunorubicin, The metabolism of Zuclopenthixol can be decreased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Deanol.]
[C02CC04, debrisoquin, Zuclopenthixol may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Zuclopenthixol.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nordazepam.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Zuclopenthixol.]
[N06AX06, nefazodone, Nefazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Niaprazine.]
[C01DX16, nicorandil, Zuclopenthixol may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Zuclopenthixol.]
[C01CA23, theodrenaline, Zuclopenthixol may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Zuclopenthixol.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Zuclopenthixol.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Zuclopenthixol is combined with Escitalopram.]
[G04BD08, solifenacin, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Olsalazine is combined with Zuclopenthixol.]
[N06AA01, desipramine, The metabolism of Zuclopenthixol can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Zuclopenthixol.]
[C09XA02, aliskiren, Zuclopenthixol may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Zuclopenthixol.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Zuclopenthixol.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Zuclopenthixol.]
[S03BA01, dexamethasone, The metabolism of Zuclopenthixol can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Oxiracetam.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Zuclopenthixol.]
[G04BD04, oxybutynin, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dexfenfluramine is combined with Zuclopenthixol.]
[A03AA01, oxyphencyclimine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Zuclopenthixol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Zuclopenthixol can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zuclopenthixol.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Zuclopenthixol.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Zuclopenthixol.]
[N06AB05, paroxetine, The metabolism of Zuclopenthixol can be decreased when combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Zuclopenthixol.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Zuclopenthixol.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Zuclopenthixol.]
[V03AH01, diazoxide, Zuclopenthixol may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Zuclopenthixol.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Zuclopenthixol.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Zuclopenthixol.]
[J01CF01, dicloxacillin, The metabolism of Zuclopenthixol can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Zuclopenthixol.]
[A03AA07, dicyclomine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may increase the neurotoxic activities of Zuclopenthixol.]
[C02DG01, pinacidil, Zuclopenthixol may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipamperone.]
[A03AB14, pipenzolate, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Zuclopenthixol.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Zuclopenthixol.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Zuclopenthixol.]
[A08AA03, diethylpropion, Diethylpropion may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[L02AA01, diethylstilbestrol, The metabolism of Zuclopenthixol can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Zuclopenthixol can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Zuclopenthixol.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Zuclopenthixol.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Zuclopenthixol.]
[C02DB01, dihydralazine, Zuclopenthixol may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Zuclopenthixol.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Zuclopenthixol.]
[J05AE08, atazanavir, The metabolism of Zuclopenthixol can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Zuclopenthixol.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Zuclopenthixol.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Zuclopenthixol.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pridinol.]
[R06AB03, dimethindene, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Zuclopenthixol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Zuclopenthixol can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Zuclopenthixol.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Zuclopenthixol can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zuclopenthixol.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Zuclopenthixol.]
[C09AA06, quinapril, Zuclopenthixol may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Zuclopenthixol.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Zuclopenthixol can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Zuclopenthixol may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Zuclopenthixol.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Zuclopenthixol.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Zuclopenthixol.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Zuclopenthixol.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Zuclopenthixol.]
[S02AA12, rifamycin SV, The metabolism of Zuclopenthixol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Zuclopenthixol can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Zuclopenthixol.]
[N05AX08, risperidone, Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Zuclopenthixol.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Zuclopenthixol.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Zuclopenthixol.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Zuclopenthixol.]
[A04AD12, aprepitant, The metabolism of Zuclopenthixol can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Zuclopenthixol.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Zuclopenthixol.]
[J05AE07, fosamprenavir, The metabolism of Zuclopenthixol can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Zuclopenthixol.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Zuclopenthixol.]
[C02KX02, ambrisentan, Zuclopenthixol may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Zuclopenthixol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Salsalate is combined with Zuclopenthixol.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Zuclopenthixol.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Zuclopenthixol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Zuclopenthixol.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Zuclopenthixol.]
[N06AA16, dothiepin, The metabolism of Zuclopenthixol can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Zuclopenthixol.]
[N06AA12, doxepin, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Zuclopenthixol.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Zuclopenthixol.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Zuclopenthixol can be decreased when combined with Simvastatin.]
[C09AA11, spirapril, Zuclopenthixol may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Zuclopenthixol.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Zuclopenthixol.]
[C07AB13, talinolol, Talinolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[H01AA01, corticotropin, The metabolism of Zuclopenthixol can be increased when combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Zuclopenthixol.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Zuclopenthixol.]
[G04CA03, terazosin, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[D01BA02, terbinafine, The metabolism of Zuclopenthixol can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Zuclopenthixol.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Thiopropazate.]
[G04BD01, emepronium, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Zuclopenthixol.]
[C09AA02, enalapril, Zuclopenthixol may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Zuclopenthixol.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Zuclopenthixol.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Zuclopenthixol.]
[C03CA04, torsemide, Zuclopenthixol may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Tramazoline.]
[C09AA10, trandolapril, Zuclopenthixol may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Zuclopenthixol.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Triclofos.]
[A03AB08, tridihexethyl, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Zuclopenthixol.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Zuclopenthixol.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Zuclopenthixol.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Zuclopenthixol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Zuclopenthixol.]
[C02CA06, urapidil, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Zuclopenthixol.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Zuclopenthixol.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Zuclopenthixol.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Zuclopenthixol.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Zuclopenthixol is combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Zuclopenthixol.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Zuclopenthixol.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Zuclopenthixol.]
[C09AA15, zofenopril, Zuclopenthixol may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Zotepine.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Zuclopenthixol.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Zuclopenthixol.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Zuclopenthixol.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.]
[N02CA02, ergotamine, Ergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Zuclopenthixol.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Zuclopenthixol.]
[H05BX01, cinacalcet, The metabolism of Zuclopenthixol can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Zuclopenthixol can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Zuclopenthixol can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Zuclopenthixol can be increased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Zuclopenthixol can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, Gepefrine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zuclopenthixol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Zuclopenthixol.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Zuclopenthixol.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Zuclopenthixol.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Zuclopenthixol.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Zuclopenthixol.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Zuclopenthixol.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Zuclopenthixol.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Zuclopenthixol.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Zuclopenthixol.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Zuclopenthixol.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Zuclopenthixol.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Zuclopenthixol.]
[R06AX12, terfenadine, The metabolism of Zuclopenthixol can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Zuclopenthixol can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Zuclopenthixol can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Zuclopenthixol.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Zuclopenthixol.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Zuclopenthixol.]
[P02CA03, albendazole, The metabolism of Zuclopenthixol can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Zuclopenthixol.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Zuclopenthixol.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Zuclopenthixol.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Zuclopenthixol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Zuclopenthixol.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Zuclopenthixol.]
[N07AX03, cevimeline, The metabolism of Zuclopenthixol can be decreased when combined with Cevimeline.]
[G04BD02, flavoxate, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Zuclopenthixol.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Floctafenine.]
[J01CF05, floxacillin, The metabolism of Zuclopenthixol can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Zuclopenthixol can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Zuclopenthixol.]
[D07AC08, fluocinonide, The metabolism of Zuclopenthixol can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Zuclopenthixol can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Zuclopenthixol.]
[N06AB03, fluoxetine, The serum concentration of Zuclopenthixol can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Zuclopenthixol.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Zuclopenthixol.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Zuclopenthixol.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Zuclopenthixol.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Zuclopenthixol.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Zuclopenthixol.]
[J05AE10, darunavir, The metabolism of Zuclopenthixol can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Zuclopenthixol may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Zuclopenthixol is combined with Eszopiclone.]
[N05AL05, amisulpride, Zuclopenthixol may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Zuclopenthixol.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Gallopamil.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Bifemelane.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Zuclopenthixol.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Zuclopenthixol.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Zuclopenthixol.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be decreased when used in combination with Zuclopenthixol.]
[J05AG04, etravirine, The metabolism of Zuclopenthixol can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Zuclopenthixol.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Zuclopenthixol.]
[A10BB01, glyburide, The metabolism of Zuclopenthixol can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Zuclopenthixol.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Zuclopenthixol.]
[C05AE01, nitroglycerin, Zuclopenthixol may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Zuclopenthixol.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Zuclopenthixol.]
[C07AB09, esmolol, Esmolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluindione.]
[C09AA09, fosinopril, Zuclopenthixol may decrease the antihypertensive activities of Fosinopril.]
[D01BA01, griseofulvin, The metabolism of Zuclopenthixol can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Zuclopenthixol may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Zuclopenthixol.]
[P01BX01, halofantrine, The metabolism of Zuclopenthixol can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Zuclopenthixol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Zuclopenthixol.]
[N05AH04, quetiapine, Quetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Zuclopenthixol.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Allobarbital.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Zuclopenthixol.]
[G03DC01, allylestrenol, The metabolism of Zuclopenthixol can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Zuclopenthixol.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Zuclopenthixol.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Zuclopenthixol.]
[J05AG01, nevirapine, The metabolism of Zuclopenthixol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Zuclopenthixol.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Zuclopenthixol.]
[C09AA04, perindopril, Zuclopenthixol may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, The metabolism of Zuclopenthixol can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Zuclopenthixol.]
[R05DA03, hydrocodone, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Zuclopenthixol can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Zuclopenthixol may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Zuclopenthixol.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Zuclopenthixol can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Zuclopenthixol.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ibuprofen is combined with Zuclopenthixol.]
[B05CB02, sodium citrate, Zuclopenthixol may increase the neurotoxic activities of Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Zuclopenthixol can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Zuclopenthixol.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.]
[N06AA02, imipramine, Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Zuclopenthixol.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Zuclopenthixol.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Zuclopenthixol.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Zuclopenthixol.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Zuclopenthixol.]
[C02CA02, indoramin, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Milnacipran.]
[A03AA30, piperidolate, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Zuclopenthixol.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Zuclopenthixol.]
[R06AE01, buclizine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Zuclopenthixol can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Zuclopenthixol.]
[C07AA01, alprenolol, Alprenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Zuclopenthixol.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Zuclopenthixol.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zuclopenthixol.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Zuclopenthixol.]
[C09AA16, imidapril, Zuclopenthixol may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Zuclopenthixol.]
[N04BX02, entacapone, The therapeutic efficacy of Entacapone can be decreased when used in combination with Zuclopenthixol.]
[J04AC01, isoniazid, The metabolism of Zuclopenthixol can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Zuclopenthixol.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Zuclopenthixol.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Zuclopenthixol.]
[L04AC07, tocilizumab, The metabolism of Zuclopenthixol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Zuclopenthixol can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Zuclopenthixol can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Zuclopenthixol.]
[V03AC03, deferasirox, The metabolism of Zuclopenthixol can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Zuclopenthixol can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Zuclopenthixol.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Zuclopenthixol.]
[N04BC09, rotigotine, Zuclopenthixol may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Zuclopenthixol.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Tiaprofenic acid is combined with Zuclopenthixol.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Zuclopenthixol.]
[C02AA05, deserpidine, Zuclopenthixol may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lacosamide.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Zuclopenthixol.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Zuclopenthixol.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Lidoflazine.]
[J01FF02, lincomycin, Zuclopenthixol may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Zuclopenthixol can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be decreased when used in combination with Zuclopenthixol.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Zuclopenthixol.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Zuclopenthixol.]
[C10AA02, lovastatin, The metabolism of Zuclopenthixol can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Zuclopenthixol.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Zuclopenthixol can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Zuclopenthixol can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Zuclopenthixol.]
[C02BB01, mecamylamine, Zuclopenthixol may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Zuclopenthixol.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Zuclopenthixol.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Medazepam.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Zuclopenthixol.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Zuclopenthixol.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Zuclopenthixol.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Zuclopenthixol.]
[C01CA11, mephentermine, Mephentermine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Zuclopenthixol.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zuclopenthixol.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Zuclopenthixol.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Meptazinol.]
[L02BG01, aminoglutethimide, The metabolism of Zuclopenthixol can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Zuclopenthixol.]
[N05AX13, paliperidone, Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Zuclopenthixol.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Zuclopenthixol.]
[H01CB03, lanreotide, The metabolism of Zuclopenthixol can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Zuclopenthixol.]
[N06BA03, methamphetamine, Metamfetamine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[A03AB07, methantheline, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Zuclopenthixol.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Zuclopenthixol can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Zuclopenthixol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Zuclopenthixol.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Zuclopenthixol is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Zuclopenthixol.]
[N05AA02, methotrimeprazine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Zuclopenthixol.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Zuclopenthixol.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Zuclopenthixol.]
[V04CG05, methylene blue, Zuclopenthixol may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Zuclopenthixol can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Zuclopenthixol.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The metabolism of Zuclopenthixol can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Zuclopenthixol.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Zuclopenthixol.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Zuclopenthixol.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.]
[C03BA08, metolazone, Zuclopenthixol may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The metabolism of Zuclopenthixol can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Zuclopenthixol.]
[V04CD01, metyrapone, The metabolism of Zuclopenthixol can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Zuclopenthixol can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Zuclopenthixol.]
[S02AA13, miconazole, The metabolism of Zuclopenthixol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Aminophenazone is combined with Zuclopenthixol.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Zuclopenthixol.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Zuclopenthixol.]
[C09CA03, valsartan, Zuclopenthixol may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[D11AX01, minoxidil, Zuclopenthixol may decrease the antihypertensive activities of Minoxidil.]
[J01FA11, miocamycin, The metabolism of Zuclopenthixol can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Zuclopenthixol can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Zuclopenthixol.]
[L03AC01, aldesleukin, The metabolism of Zuclopenthixol can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Zuclopenthixol can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Zuclopenthixol.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Zuclopenthixol.]
[L04AB05, certolizumab pegol, The metabolism of Zuclopenthixol can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Zuclopenthixol.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Zuclopenthixol.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Zuclopenthixol.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Zuclopenthixol.]
[G04CA04, silodosin, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[R03BB01, ipratropium bromide, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Zuclopenthixol can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N03AB05, fosphenytoin, The metabolism of Zuclopenthixol can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Zuclopenthixol.]
[J01CF06, nafcillin, The metabolism of Zuclopenthixol can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Zuclopenthixol.]
[V03AB15, naloxone, The metabolism of Zuclopenthixol can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Zuclopenthixol.]
[L04AC03, anakinra, The metabolism of Zuclopenthixol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Zuclopenthixol.]
[N06BA01, amphetamine, Amphetamine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Zuclopenthixol.]
[A10BG01, troglitazone, The metabolism of Zuclopenthixol can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Zuclopenthixol can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The therapeutic efficacy of Tolcapone can be decreased when used in combination with Zuclopenthixol.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Zuclopenthixol.]
[S03AA01, neomycin, Neomycin may increase the neurotoxic activities of Zuclopenthixol.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Zuclopenthixol.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Zuclopenthixol.]
[N05AX14, iloperidone, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Zuclopenthixol may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Zuclopenthixol can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nialamide.]
[C08CA04, nicardipine, Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Zuclopenthixol.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Zuclopenthixol.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Zuclopenthixol.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nitrendipine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Zuclopenthixol.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Zuclopenthixol.]
[C02DD01, nitroprusside, Zuclopenthixol may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Nomifensine.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Zuclopenthixol.]
[G03DC02, norethindrone, The metabolism of Zuclopenthixol can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Zuclopenthixol.]
[C02KX01, bosentan, The metabolism of Zuclopenthixol can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[R05DA07, noscapine, The metabolism of Zuclopenthixol can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Zuclopenthixol.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Zuclopenthixol.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Zuclopenthixol.]
[J01FA05, oleandomycin, The metabolism of Zuclopenthixol can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Zuclopenthixol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Zuclopenthixol can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Opium.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Zuclopenthixol.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Zuclopenthixol.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[P02BA02, oxamniquine, The metabolism of Zuclopenthixol can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Zuclopenthixol.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Zuclopenthixol.]
[C07AA02, oxprenolol, Oxprenolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Zuclopenthixol.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Zuclopenthixol.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Zuclopenthixol.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Zuclopenthixol.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Zuclopenthixol.]
[N05AH05, asenapine, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.]
[M03AC01, pancuronium, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Zuclopenthixol.]
[N05CC05, paraldehyde, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Zuclopenthixol can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Zuclopenthixol.]
[G04BD11, fesoterodine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Zuclopenthixol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Zuclopenthixol.]
[N05CA01, pentobarbital, The metabolism of Zuclopenthixol can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Zuclopenthixol.]
[C08EX02, perhexiline, The metabolism of Zuclopenthixol can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Zuclopenthixol.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Zuclopenthixol.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.]
[A10BA01, phenformin, The metabolism of Zuclopenthixol can be decreased when combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Zuclopenthixol.]
[N03AA02, phenobarbital, The metabolism of Zuclopenthixol can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Zuclopenthixol.]
[A08AA01, phentermine, Phentermine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[V03AB36, phentolamine, Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[M02AA01, phenylbutazone, The metabolism of Zuclopenthixol can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Zuclopenthixol.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Zuclopenthixol.]
[N03AB02, phenytoin, The metabolism of Zuclopenthixol can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Zuclopenthixol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Zuclopenthixol.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Zuclopenthixol.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Zuclopenthixol.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Zuclopenthixol.]
[C07AA03, pindolol, Pindolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[J05AE01, saquinavir, The metabolism of Zuclopenthixol can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Zuclopenthixol can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Zuclopenthixol.]
[C09CA02, eprosartan, Zuclopenthixol may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Zuclopenthixol.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Zuclopenthixol.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Zuclopenthixol.]
[N02CX01, pizotyline, Zuclopenthixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Zuclopenthixol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Zuclopenthixol can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Zuclopenthixol.]
[L04AC08, canakinumab, The metabolism of Zuclopenthixol can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Zuclopenthixol may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, Zuclopenthixol may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Zuclopenthixol can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, Practolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Zuclopenthixol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Zuclopenthixol.]
[C02CA01, prazosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[S03BA02, prednisolone, The metabolism of Zuclopenthixol can be increased when combined with Prednisolone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Zuclopenthixol.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Zuclopenthixol.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Zuclopenthixol.]
[P01BA03, primaquine, The metabolism of Zuclopenthixol can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Zuclopenthixol can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Zuclopenthixol can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Zuclopenthixol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Zuclopenthixol.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Zuclopenthixol.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Zuclopenthixol.]
[C10AB05, fenofibrate, The metabolism of Zuclopenthixol can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Zuclopenthixol.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Zuclopenthixol.]
[G03DA04, progesterone, The metabolism of Zuclopenthixol can be decreased when combined with Progesterone.]
[N05AA03, promazine, Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[R06AD02, promethazine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Zuclopenthixol.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Propanidid.]
[A03AB05, propantheline, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Periciazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05CM06, propiomazine, Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Zuclopenthixol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zuclopenthixol.]
[C07AA05, propranolol, Propranolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Zuclopenthixol.]
[B01AC09, epoprostenol, Zuclopenthixol may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Zuclopenthixol.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the sedative and stimulatory activities of Zuclopenthixol.]
[N05AX12, aripiprazole, Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[A03AB15, diphemanil, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Zuclopenthixol.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Zuclopenthixol.]
[C01BA01, quinidine, Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[P01BC01, quinine, The metabolism of Zuclopenthixol can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Zuclopenthixol can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Zuclopenthixol may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Zuclopenthixol.]
[J04AB02, rifampin, The metabolism of Zuclopenthixol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Zuclopenthixol.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Zuclopenthixol.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Zuclopenthixol.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Zuclopenthixol is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Zuclopenthixol.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Zuclopenthixol.]
[S01FA02, scopolamine, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Zuclopenthixol.]
[N04BD01, selegiline, The therapeutic efficacy of Selegiline can be decreased when used in combination with Zuclopenthixol.]
[H01CB01, somatostatin, The metabolism of Zuclopenthixol can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Zuclopenthixol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Zuclopenthixol.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Zuclopenthixol.]
[D07AB02, hydrocortisone butyrate, The metabolism of Zuclopenthixol can be increased when combined with Hydrocortisone butyrate.]
